Is CSL a dud or a deliverer?
While CSL has become a real head scratcher, a fall in its share price is understandable. But has the fall been excessive? Its sell off looks way over the top.
Investment analysis, share recommendations, and market insights.
While CSL has become a real head scratcher, a fall in its share price is understandable. But has the fall been excessive? Its sell off looks way over the top.
Although I’ve never been a gold bug, I have been investing in gold over the last few months. Let me explain how I invest in gold.
In our “HOT” stock column today, Raymond Chan, Adviser & Head of Asian Desk explains why the Morgan’s team maintains a buy rating on Amcor (AMC).
Here are four biotech ETFs for long-term contrarian investors to consider.
Every investor is looking for meaningful capital gain when they buy a stock. Here are two candidates that look capable of delivering that in 2026.
Here are three ETFs that could benefit from Great Power contestation for natural resources.
Here are three mixed-asset Exchange Traded Funds (ETFs) to consider as you engage in portfolio construction and maintenance.
Kicking off the year, the challenge is to know what stocks, sectors and markets will be winners. Of course, it’s our job to discover this, so here’s what I think.
We’ve made some changes to our income and growth portfolios for 2026 to consider the dominant investment themes we expect to apply. We’ve also rebalanced the portfolios.
Additive manufacturing (3D printing) is going through rapid global growth in terms of scale and range of applications. Australia has significant technological expertise in this field. Here are three ASX stocks at the forefront of AM that are all building deep engagement with defence customers.
You don't have credit card details available. You will be redirected to update payment method page. Click OK to continue.